Susquehanna Fundamental Investments’s Fulcrum Therapeutics FULC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-111,582	Closed	-$1.03M	–	619
2025 Q3	$1.03M	Hold	111,582	–	–	0.04%	325
2025 Q2	$768K	Sell	111,582 -39,061	-26%	-$209K	0.02%	493
2025 Q1	$434K	Sell	150,643 -62,570	-29%	-$230K	0.01%	879
2024 Q4	$1M	Buy	+213,213	New	+$787K	0.01%	707
2023 Q3	–	Sell	-22,594	Closed	-$74.6K	–	457
2023 Q2	$74.6K	Sell	22,594 -18,940	-46%	-$55.6K	﹤0.01%	614
2023 Q1	$118K	Sell	41,534 -43,024	-51%	-$385K	﹤0.01%	893
2022 Q4	$616K	Buy	84,558 +26,758	+46%	+$174K	0.01%	803
2022 Q3	$468K	Buy	+57,800	New	+$414K	0.01%	1043
2021 Q4	–	Sell	-57,726	Closed	-$1.63M	–	1559
2021 Q3	$1.63M	Buy	+57,726	New	+$1.09M	0.03%	671

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Susquehanna Fundamental Investments's FULC Position: Q4 2025 in Review

Susquehanna Fundamental Investments sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 111,582 shares — an estimated $1.03M sold.

Susquehanna Fundamental Investments first reported a position in FULC in Q3 2021 and held it in 9 quarters. The position peaked at $1.63M in Q3 2021. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

Susquehanna Fundamental Investments reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 111,582 Fulcrum Therapeutics shares in Q4 2025, an estimated $1.03M.
Susquehanna Fundamental Investments first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 9 quarters.
Susquehanna Fundamental Investments's Fulcrum Therapeutics position peaked at $1.63M in Q3 2021.
172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2025, filed 17 Feb 2026.